Five additional R&D projects has been
opened for negotiation in Cuba
José A. Acosta
Havana – August, 12. The Center for Genetic
Engineering and Biotechnology (CIGB)
opened at least five new projects to negotiation with foreign companies.
These R&D
projects has been included in the CIGB’s negotiation portfolio,
which has been
published in the web site http://gndp.cigb.edu.cu , to facilitate
the access to the
scientific community, companies and research institutions to the
most up to date
R&D results.
CIGB is looking for licensing agreements to carry out clinical
trials and registration of
a synthetic vaccine targeting the Haemophilus influenzae type b
(Hib) in the first
world markets. Last year, the CIGB received final approval from
the Cuban regulatory
authority for the vaccine against Hib , which is manufactured in
a cGMP plant
according to the highest regulatory standards. Last month was published
in Science
an article about this vaccine.
The CIGB has also developed a growth stimulator formula (Acuabio
1) able to improve
surviving, growth and homogeneity during aquatic farming, when
used on aquatic
species. This very promising project has been recently offered
for negotiation by the
CIGB.
A third project for increasing productivity in aquaculture by using
non hormone
treated all males mono sex tilapia production, has also been opened
for negotiations
by the CIGB.
A new technology platform for fast and reliable expression of recombinant
proteins
in the milk of non transgenic animals has also been included in
the CIGB’s negotiation
portfolio. The Cuban institution is searching for R&D alliances
for long term tissue
specific expression in ruminants and microbiological validation
of a manufacturing
process.
The fifth R&D project opened for negotiation by the CIGB has
been the development
of an effective biological nematicide (HeberNem) based on Corynebacterium
paurometabolum C924 strain. The interest of the CIGB is focused
on evaluation
agreements based on testing HeberNem effect in other countries.
For more detail information about the Cuban biotech sector you
will visit
http://gndp.cigb.edu.cu , www.cim.sld.cu .
About CIGB
Heber Biotec SA is the
commercial branch of the Center for Genetic Engineering and
Biotechnology (CIGB). The CIGB is one of the Centers of the Scientific
Pole in Cuba
devoted to research, development and manufacturing of human biotech
and agro bio
products, and Heber Biotec is the marketing company. CIGB utilizes
its platform
technology and development capabilities to facilitate the rapid,
cost-effective
discovery and development of novel drugs.
Contact person:
Ernesto López Mola
Business Development Group, GNDP
CIGB
Phone e: (53 7) 271 2397
Fax: (53 7) 33 6008
Email: ernesto.lopez@cigb.edu.cu
Web page: http://gndp.cigb.edu.cu
|
